Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

Gilead (GILD) stock in focus as its HIV anti-viral lenacapavir shows promise in HIV prevention with once-yearly PrEP ...

The Trump administration has cut around 100 employees, or roughly 10%, of the federal agency that oversees mental and ...

A clinical trial published in The Lancet suggests that a yearly injection of lenacapavir, developed by Gilead Sciences, is ...

A yearly injection to protect against HIV is safe and shows promise as a prevention method with long-lasting effects, according to the results of a c ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...